Epix nets Australian approval

MRI contrast developer Epix Pharmaceuticals has received approval from the Australian Therapeutic Goods Administration (TGA) to market its Vasovist blood-pool imaging agent.

Vasovist is indicated for contrast-enhanced MR angiography for visualization of abdominal or limb vessels in patients with suspected or known vascular disease. The agent is now available in 27 countries, according to the Lexington, MA-based firm.

By AuntMinnie.com staff writers
September 20, 2006

Related Reading

Epix regains Nasdaq symbol, September 15, 2006

FDA rejects Epix appeal, August 28, 2006

Epix, Predix complete merger, August 17, 2006

Epix, Predix shareholders approve merger, August 15, 2006

Epix nears Australia approval for Vasovist, August 14, 2006

Copyright © 2006 AuntMinnie.com

Page 1 of 605
Next Page